March 2024 in “Cleveland Clinic journal of medicine” Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.
October 2017 in “Chinese Journal of Dermatology” 27 citations
,
July 1983 in “Journal of Investigative Dermatology”
26 citations
,
March 2003 in “Pediatrics” Oral steroids may effectively treat recurrent intussusception in children with ILH, possibly avoiding surgery.
January 1978 in “Enlighten: Theses (The University of Glasgow)” Inhibiting testosterone 5alpha-reductase may help treat benign prostatic hyperplasia.
1054 citations
,
February 1998 in “The New England Journal of Medicine” Finasteride reduces urinary issues and surgery need in men with enlarged prostates by over 50%.
1040 citations
,
October 1992 in “The New England Journal of Medicine” Finasteride effectively treats BPH but may increase sexual dysfunction risk.
150 citations
,
June 1999 in “Oncogene” 33 citations
,
July 2009 in “Therapeutics and Clinical Risk Management” Finasteride effectively reduces prostate size and lowers surgery risk in men with benign prostatic hyperplasia.
12 citations
,
January 1998 in “Drug safety” Finasteride helps reduce prostate size and symptoms in BPH but is less effective than terazosin and works best for larger prostates.
4 citations
,
September 2022 in “Experimental and Сlinical Urology” 5-alpha reductase inhibitors help with benign prostatic hyperplasia but don't cure it, and more research is needed.
2 citations
,
March 2020 in “Baghdad Science Journal” Finasteride effectively reduces DHT and E2 levels, helping with prostate enlargement.
2 citations
,
February 2006 in “Mayo Clinic Proceedings” Finasteride is effective for hair loss and may help prevent prostate cancer without increasing high-grade cancer risk.
September 2025 in “Consilium Medicum” 5α-reductase inhibitors help manage symptoms of benign prostatic hyperplasia and may also prevent prostate cancer and treat hair loss.
184 citations
,
January 2000 in “European Urology” Blocking the enzyme that turns testosterone into DHT can safely and effectively treat enlarged prostate.
52 citations
,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
14 citations
,
November 2006 in “Current Medicinal Chemistry” New treatments for enlarged prostate are being developed to be more effective and have fewer side effects.
13 citations
,
August 2013 in “Journal of pharmaceutical sciences” Researchers created a skin patch that delivers two drugs for treating enlarged prostate, which may improve patient use and dosage control.
1 citations
,
November 2021 in “Société internationale d'urologie journal” Doctors should adjust how they treat men with prostate-related urinary problems during and after the COVID-19 pandemic.
December 2018 in “Actas urológicas españolas” 5-alpha reductase inhibitors may have additional effects on cancer, mental health, heart health, and hormone levels beyond treating prostate enlargement.
December 1981 in “Pediatric Research” 1 citations
,
December 2020 in “Panacea Journal of Medical Sciences” Metabolic syndrome worsens treatment outcomes for urinary symptoms in men with enlarged prostate.
December 2025 in “Journal of Inflammation Research” The treatment improved prostate health in mice.
17 citations
,
August 2011 in “Current Medicinal Chemistry” New treatments for enlarged prostate are being developed, some of which may be more effective than current medications.
128 citations
,
March 1996 in “Journal of Investigative Dermatology” 467 citations
,
May 1999 in “Molecular Cell” Activating c-Myc in skin causes rapid cell growth and changes, but these effects are reversible.
156 citations
,
October 1996 in “Science of The Total Environment” Tributyltin exposure causes sex changes, sterilization, and decline in the snail Ocinebrina aciculata, risking its extinction.
127 citations
,
July 2002 in “EMBO journal” Normal skin cell renewal doesn't need RAR signaling, but vitamin A-related skin thickening does.
107 citations
,
June 1997 in “PubMed” EGFR is essential for normal hair development and follicle differentiation.
96 citations
,
October 1987 in “The Journal of Clinical Endocrinology & Metabolism” Chronic GnRHa treatment can help manage endometrial hyperplasia and reduce ovarian androgen excess in PCO patients.